Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMS Foresees Generics Market Surging Ahead

This article was originally published in PharmAsia News

Executive Summary

Pharmaceutical research firm IMS expects the 2008 global pharmaceutical and health care industry to grow at 5 percent to 6 percent, a rate slightly less than the 6 percent to 7 percent of 2007. Drugs enjoying some $20 billion worth of sales will lose their patent this year, making space for generics to proliferate at 14 percent to 15 percent to reach over $70 billion, thanks to rising demand worldwide. Generics-producing countries such as China, Brazil, Mexico, South Korea, India, Turkey and Russia are set to expand their market at 12 percent to 13 percent to hit a total of $90 billlion in 2008. China, growing at 16 percent, ranks ninth on the global pharmaceutical market. IMS predicts that domestic demand will propel the country to sixth position in 2011. (Click here for more - Chinese Language)

You may also be interested in...



Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

WHO Prequalifies Celltrion’s Rituximab

Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.

EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times

26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel